Physician profile
Andrew Cusack
NPI 1578827523
$4,236.43
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,353 · 2020: $987 · 2021: $850 · 2022: $46.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.46 | 2019-2021 | |
| Glaxosmithkline, LLC. | $505.64 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $421.93 | 2019-2021 | |
| Novo Nordisk INC | $323.43 | 2019-2021 | |
| Pfizer INC. | $281.82 | 2019-2021 | |
| Lilly USA, LLC | $254.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $242.55 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $219.49 | 2019-2020 | |
| Amgen INC. | $205.91 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $148.58 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $145.64 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $132.60 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.58 | 2019-2021 | |
| Abbott Laboratories | $86.46 | 2020-2022 | |
| Amarin Pharma, INC. | $85.27 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $66.90 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $61.76 | 2019 | |
| Astellas Pharma US INC | $57.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.13 | 2019-2020 | |
| Mylan Specialty L.P. | $31.61 | 2019 | |
| Abbvie INC. | $31.34 | 2021 | |
| Nestle Healthcare Nutrition INC. | $29.91 | 2021 | |
| Esperion Therapeutics, INC. | $27.66 | 2020 | |
| Allergan, INC. | $26.00 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.94 | 2019 | |
| Sanofi Pasteur INC. | $18.40 | 2019 | |
| Phadia US INC. | $16.84 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.79 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.96 | 2020 | |
| Valeritas, INC. | $14.33 | 2019 | |
| Eisai INC. | $14.31 | 2020 | |
| Corcept Therapeutics | $13.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.31 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cusack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.